NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium, will present a corporate update at the 2014 BIO International Convention in San Diego, CA on June 26th, 2014.
The schedule for the presentation is as follows:
Date: Thursday, June 26, 2014
Time: 11:00 AM PDT
Room: Pacific Beach
Dr. Kaushik J. Dave, President and CEO of Actinium, commented “We look forward to sharing details of our ongoing programs for innovative targeted payload immunotherapeutics at the annual BIO International Convention, the largest global event for the biotechnology industry. We continue to work aggressively to advance Iomab™-B towards a pivotal trial in refractory and relapsed AML patients over the age of 55 and Actimab-A, which is currently in development in a Phase 1/2 trial for newly diagnosed AML patients. As we move our candidates forward, we remain excited about leveraging the broad utility of our delivery platform for a variety of cancer types and settings.”
Dr. Dave and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or firstname.lastname@example.org.
About BIO International Convention 2014
The annual BIO International Convention is the largest global event for the biotechnology industry. The Convention attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. For policymakers, legislators, regulators and public officials, the BIO International Convention is the world’s most important venue to meet and exchange high-level dialogue with industry leaders, U.S. public policy officials, and representatives from more than 60 other countries. The Convention offers a plethora of events designed to explore technological and policy solutions to global challenges using effective instruments that encourage innovation, investment and growth. For further information, please visit http://convention.bio.org/.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.